Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This clinical trial is designed to find better treatments for adults with classical Hodgkin lymphoma, a type of blood cancer. Researchers are testing a combination of existing cancer drugs with a newer medicine called Brentuximab Vedotin (also known as Adcetris) and another drug called Nivolumab (Opdivo). The main aim is to see if these treatments can completely clear the cancer from the body. We also want to understand any side effects and how long the positive effects of the treatment might last. By exploring different ways to use these medicines, we hope to improve the chances of recovery for people with this condition. This is an early-stage study, meaning we are learning more about these combinations.
At a glance
What is this study about?
This research study is looking for new and improved ways to treat classical Hodgkin lymphoma. This is a type of cancer that starts in white blood cells called lymphocytes, which are part of your immune system. Doctors and scientists are always looking for better treatments to help people recover and live healthier lives.
In this study, participants will receive a combination of medicines. These include Dacarbazine and Doxorubicin, which are standard chemotherapy drugs used to treat cancer. They will also receive Brentuximab Vedotin (Adcetris), which is a targeted therapy designed to find and kill cancer cells, and Nivolumab (Opdivo), an immunotherapy that helps your body's immune system fight the cancer.
The main goal of this study is to see how many people experience a complete remission, meaning the cancer can no longer be detected, after treatment. We'll also be carefully watching for any side effects and seeing how the treatments affect people's overall health and the cancer's return over time. This is a 'Phase II' study, which means we are exploring whether these specific combinations of treatments are effective and safe enough to be tested in larger studies later on.
Key takeaways
- This study explores new treatment combinations for classical Hodgkin lymphoma.
- It aims to see if the cancer can be completely removed (complete remission).
- Treatments include standard chemotherapy along with newer targeted and immunotherapy drugs.
- Participation involves regular hospital visits for treatment, tests, and monitoring.
- Adults aged 18 and over with classical Hodgkin lymphoma may be eligible.
- You have the full right to withdraw from the study at any point.
Who may be eligible?
This study is looking for adult patients who have been diagnosed with classical Hodgkin lymphoma. Both men and women are welcome to take part. To be eligible, you need to be at least 18 years old – there's no upper age limit, as long as you're well enough otherwise.
The research team will carry out a thorough check of your medical history and current health to make sure this study is right for you. There might be other specific health conditions or medications that would mean you couldn't join, but the doctors will discuss all of this with you in detail.
It's important that you understand what's involved and are comfortable taking part. The study team will explain everything clearly and answer any questions you have to help you decide if this is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with classical Hodgkin lymphoma?
- Are you generally well enough to take part in a study?
- Are you able to attend regular hospital appointments?
What does participation involve?
If you decide to take part in this study, you will receive a combination of medicines through an infusion (into your vein) over several treatment cycles. The exact number of visits and the schedule will be explained in detail by the study team, but you can expect regular appointments for treatment, check-ups, and tests.
During your participation, you will have various assessments. This includes physical examinations, blood tests to check your general health and how well the treatment is working, and scans to monitor the cancer. The study team will be checking for any side effects and making sure you are as comfortable as possible.
After your main treatment finishes, there will be follow-up appointments to continue monitoring your health and the cancer. The total duration of your involvement could range from several months for the active treatment phase to longer for follow-up, but the study team will provide you with a clear timeline.
Potential risks and benefits
Locations (4)
- —UnverifiedSpain
- —UnverifiedCzechia
- —UnverifiedItaly
- —UnverifiedPoland
Common questions
What is classical Hodgkin lymphoma?
It's a type of cancer that starts in white blood cells called lymphocytes, which are part of your body's immune system.
What medicines are being used in this study?
You would receive a combination of Dacarbazine, Doxorubicin, Brentuximab Vedotin (Adcetris), and Nivolumab (Opdivo).
What does a 'complete remission' mean?
It means medical tests show no sign of cancer in your body after treatment.
How long will I be in the study?
The study involves a period of active treatment over several months, followed by longer-term follow-up visits. The exact duration will be discussed with you.
Can I stop participating in the study if I want to?
Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your standard medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.